1 Glorious Growth Stock Down 84% to Buy on the Dip in June

Docusign’s new AI-powered Intelligent Agreement Management platform is gaining traction and now represents 12.6% of annual recurring revenue, up from 10.8% three months earlier. Fiscal Q1 2027 revenue rose 9% to $830.2 million, above guidance of $822 million-$826 million, while GAAP profit increased 8% to $78.2 million. The stock trades at 3.1x sales and 30.9x trailing earnings, below its historical valuation, suggesting room for a longer-term rerating if IAM scales.

Analysis

DOCU is transitioning from a post-pandemic normalization story to an AI monetization story, but the market is still pricing it like a low-growth legacy SaaS name. The important second-order effect is not just revenue acceleration; it is mix shift toward workflow software with deeper embedding, which should improve retention, raise switching costs, and make renewal cycles less cyclical than pure e-signature demand.

The near-term setup is favorable because management is prioritizing margin discipline while IAM is still early in penetration. That creates a cleaner earnings path over the next 2-4 quarters: even mid-single-digit top-line growth can translate into outsized EPS leverage if sales efficiency stays tight. The key risk is that AI features become table stakes faster than investors expect, limiting willingness to pay and making IAM a feature bundle rather than a standalone platform.

Consensus likely underestimates how long enterprise workflow transformations take. If IAM is gaining share of ARR from a low base, the main catalyst is not a single quarter beat but a sustained sequence of larger deployments over 12-18 months; conversely, one or two large pilots failing to expand would quickly deflate the AI narrative. The stock looks inexpensive versus its own history, but the right question is whether the multiple re-rates on ARR mix improvement or stalls until growth re-accelerates materially.

Key Decisions for Investors

• Long DOCU on a 6-12 month horizon; use a starter position near current levels with a target of a re-rating toward 5-6x sales if IAM adoption continues to compound, versus downside to low-20s if growth stays stuck in high-single digits.
• Buy DOCU Jan-2027 call spreads to express the AI-platform re-rating with defined risk; best if entered on any post-earnings pullback, since the catalyst is adoption trajectory rather than a single quarter.
• Pair trade: long DOCU / short a basket of slower-growth legacy workflow SaaS names over 3-6 months, betting that AI-native contract management wins incremental budget share even before headline growth inflects.
• Sell out-of-the-money puts on DOCU only after earnings if implied volatility spikes; the stock has support from valuation and profitability, but the position should be sized for execution-risk surprises.
• Reduce exposure if IAM remains below mid-teens of ARR after the next 2 reporting cycles; that would suggest AI is not yet driving enough willingness to pay to justify multiple expansion.